pharmaceutical preparation of chemically modified oral calcitonin for the treatment of osteoporosis

Pharmaceutical preparation of chemically modified oral calcitonin for the treatment of osteoporosis, osteoarthritis, Paget disease, hypercalcemia, fibromyalgia, osteoporotic fracture pains and bone fracture pains, peripheral and neuropathic pains, obesity, migraine headaches, bone mineral loss, calcinosis, and postmenopausal breast cancer (as an aromatase inhibitor)